美諾華(603538.SH):2個藥品預中標第四批全國藥品集中採購
格隆匯2月3日丨美諾華(603538.SH)公佈,國家聯合採購辦公室)開展了第四批國家組織藥品集中採購和使用工作。公司全資子公司美諾華天康和合資公司科爾康美諾華已視同通過國家藥品監督管理局仿製藥質量和療效一致性評價的產品培哚普利叔丁胺片(4mg)、普瑞巴林膠囊(75mg,150mg)擬中選本次集中採購。
美諾華天康和科爾康美諾華分別於2020年10月、2020年12月取得培哚普利叔丁胺片和普瑞巴林膠囊藥品註冊批件,擬中標產品2020年無銷售收入。
本次集中採購是國家組織的第四批藥品集中帶量採購,均為首次被納入國家集中採購藥品目錄且中標。採購週期中,醫療機構將優先使用本次藥品集中採購中選藥品,並確保完成約定採購量。若公司後續簽訂採購合同並實施後,不僅能增加公司營業收入,還將有利於增強公司製劑產品競爭力,提高市場佔有率及公司品牌影響力,對公司未來經營具有積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.